D.E. Shaw & Co
FLNA

D.E. Shaw & Co’s Filana Therapeutics FLNA Stock Holding History

D.E. Shaw & Co’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-10,000
Closed -$295K – 4812
2022
Q4 		$295K Hold
10,000
– – ﹤0.01% 4094
2022
Q3 		$418K Hold
10,000
– – ﹤0.01% 4137
2022
Q2 		$281K Hold
10,000
– – ﹤0.01% 4391
2022
Q1 		$371K Hold
10,000
– – ﹤0.01% 4541
2021
Q4 		$437K Hold
10,000
– – ﹤0.01% 4474
2021
Q3 		$621K Hold
10,000
– – ﹤0.01% 3951
2021
Q2 		$854K Buy
+10,000
New +$536K ﹤0.01% 3673

Other funds holding FLNA

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $1.92B AUM 70.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

D.E. Shaw & Co's FLNA Position: Q2 2026 in Review

D.E. Shaw & Co reduced its Filana Therapeutics (FLNA) stake by 13% in Q2 2026, selling an estimated $106K and leaving 485,025 shares worth $577K. The position accounts for ﹤0.01% of the portfolio, ranked #4111.

D.E. Shaw & Co first reported a position in FLNA in Q2 2013 and has held it in 30 quarters since. The position peaked at $5.13M in Q2 2021. 84 funds tracked by Wall St. Rank hold FLNA as of Q2 2026.

  • D.E. Shaw & Co held 485,025 shares of Filana Therapeutics worth $577K as of Q2 2026.
  • D.E. Shaw & Co sold 74,180 Filana Therapeutics shares in Q2 2026, an estimated $106K.
  • Filana Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #4111 holding.
  • D.E. Shaw & Co first reported a position in Filana Therapeutics in Q2 2013 and has held it in 30 quarters since.
  • D.E. Shaw & Co's Filana Therapeutics position peaked at $5.13M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Filana Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.